中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月15日星期二
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药
  内分泌研究 本期目录 | 过刊浏览 | 高级检索 |
艾灸联合厄贝沙坦片治疗糖尿病肾病Ⅲ、Ⅳ期的临床观察
邱 悦 虞成毕 周文娣
 
江西省九江市中医医院内分泌科,江西九江 332000
Clinical observation of moxibustion combined with Irbesartan Tablets in the treatment of diabetic nephropathy stage Ⅲand Ⅳ
QIU Yue YU Chengbi ZHOU Wendi#br#
Department of Endocrinology,Jiujiang Hospital of Traditional Chinese Medicine,Jiangxi Province,Jiujiang 332000,China
全文: PDF (475 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 
 目的 探讨糖尿病肾病(DKD)Ⅲ、Ⅳ期患者应用艾灸联合厄贝沙坦片治疗的效果。方法 选取2020 年8 月至2021 年8 月于九江市中医医院就诊的80 例DKD 患者为研究对象,采用随机数字表法分为对照组和观察组,每组各40 例。对照组予以基础治疗,并口服厄贝沙坦片,观察组加用艾灸治疗。比较两组的临床疗效、中医证候积分、血糖水平、炎症因子水平、生化指标及不良反应。结果 观察组的临床总有效率高于对照组,差异有统计学意义(P<0.05);观察组治疗后的中医证候积分低于对照组,差异有统计学意义(P<0.05);血糖方面,空腹血糖(FPG)、餐后2 h 血糖(2 hPG)低于对照组,差异有统计学意义(P<0.05);炎症因子方面,肿瘤坏死因子α(TNF-α)、超敏C 反应蛋白(hs-CRP)和白介素-6(IL-6)水平低于对照组,差异有统计学意义(P<0.05);生化指标方面,尿素氮(BUN)、血肌酐(Scr)、24 h 尿蛋白定量(mALB)、尿微量白蛋白(MAU)、尿白蛋白/肌酐比值(ACR)、尿视黄醇结合蛋白(RBP)水平低于对照组,差异有统计学意义(P<0.05)。两组未见明显不良反应。结论 DKD Ⅲ、Ⅳ期患者应用艾灸联合厄贝沙坦片治疗可改善血糖水平及肾功能,缓解临床症状,减轻炎症反应,效果确切,安全性好,值得推广。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
邱 悦
虞成毕
周文娣
关键词 糖尿病肾病艾灸厄贝沙坦片血糖水平炎症因子水平生化指标    
Abstract
 Objective To investigate the effect of moxibustion combined with Irbesartan Tablets on diabetic nephropathy(DKD)patients in stage Ⅲand Ⅳ.Methods A total of 80 DKD patients treated in Jiujiang Hospital of Traditional Chinese Medicine from August 2020 to August 2021 were selected as the study objects,and were divided into control group and observation group by random number table method,with 40 cases in each group.The control group was treated with basic treatment and oral Irbesartan Tablets,and the observation group was added with moxibustion.The clinical efficacy,traditional Chinese medicine syndrome score,blood glucose level,inflammatory factor level,biochemical indexes and adverse reactions were compared between the two groups.Results The total clinical effective rate of the observation group was higher than that of the control group,the difference was statistically significant (P<0.05).The traditional Chinese medicine syndrome scores of the observation group after treatment were lower than those of the control group,and the differences were statistically significant(P<0.05).In terms of blood glucose,fasting blood glucose(FPG)and 2 h postprandial blood glucose(2 hPG)were lower than those in control group,with statistical significances (P<0.05).In terms of inflammatory factors,the levels of tumor necrosis factor α (TNF-α),hypersensitive C-reactive protein (hs-CRP)and interleukin-6 (IL-6)were lower than those of control group,with statistical significances (P<0.05).In terms of biochemical indexes,the levels of urea nitrogen (BUN),blood creatinine (Scr),24 h urinary protein quantity (mALB),urinary microalbumin (MAU),urinary albumin/creatinine ratio(ACR)and urinary retinol binding protein(RBP)were lower than those of control group,and the differences were statistically significants (P<0.05).No obvious adverse reactions were observed in the two groups.Conclusion The application of moxibustion combined with Irbesartan Tablets in the treatment of patients with DKD Ⅲand Ⅳcan improve blood glucose level and renal function,relieve clinical symptoms,reduce inflammatory reaction,with exact effect and good safety,which is worthy of promotion.
Key wordsDiabetic nephropathy    Moxibustion    Irbesartan Tablets    Blood glucose levels    Levels of inflammatory factors    Biochemical indicators
    
基金资助:江西省中医药管理局科技计划项目(2021B549)。
引用本文:   
邱 悦;虞成毕;周文娣. 艾灸联合厄贝沙坦片治疗糖尿病肾病Ⅲ、Ⅳ期的临床观察[J]. 中国当代医药, 2024, 31(12): 52-56.
QIU Yue;YU Chengbi ;ZHOU Wendi. Clinical observation of moxibustion combined with Irbesartan Tablets in the treatment of diabetic nephropathy stage Ⅲand Ⅳ. 中国当代医药, 2024, 31(12): 52-56.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2024/V31/I12/52
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载